Syn-AKE Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Syn-AKE?
• Syn-AKE Molecular Structure and Core Properties
• How Syn-AKE Works: Mechanisms Being Investigated
• Syn-AKE Major Areas of Research
• Syn-AKE Pharmacokinetics and Biological Distribution
• Syn-AKE Research Limitations and Evidence Gaps
• Syn-AKE Regulatory and Research Status
• Syn-AKE Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Neuromuscular modulation, dermatological aging models, topical delivery research, anti-aging pathway studies
• First Synthesized: 2004; patent granted 2006 by Pentapharm Ltd.
• Molecular Weight: 495.58 g/mol
• Research Status: Predominantly preclinical and manufacturer-sponsored; no registered Phase I, II, or III human clinical trials identified
• Key Mechanisms: Nicotinic acetylcholine receptor (nAChR) blocking, SIRT1 binding (computational), matrix metalloproteinase modulation (computational), antioxidant activity (in lab dishes)
• Published Studies: Limited independent peer-reviewed research; primary efficacy data from one 28-day human study of 50 subjects
• Clinical Trial Status: No registered clinical trials confirmed on ClinicalTrials.gov
• Regulatory Classification: Cosmetic ingredient in topical formulations (United States and EU); not classified as a pharmaceutical drug; research use only in non-cosmetic contexts

What is Syn-AKE?

Syn-AKE is a synthetic biomimetic tripeptide designed to replicate the neuromuscular blocking activity of Waglerin-1, a bioactive peptide isolated from the venom of the Temple Viper (Tropidolaemus wagleri). In nature, Waglerin-1 causes muscle paralysis in prey by blocking neuromuscular transmission at the nicotinic acetylcholine receptor (nAChR) — the protein that receives nerve signals telling muscles to contract. Researchers at Pentapharm Ltd. isolated the minimal amino acid sequence responsible for this receptor activity and synthesized a simplified, topically deliverable version that retains selective receptor targeting while eliminating the systemic toxicity of the full venom compound.

The result is a tripeptide designated chemically as H-beta-Ala-Pro-Dab-NH-benzyl diacetate, also known by its INCI name Tripeptide-3 or Dipeptide Diaminobutyroyl Benzylamide Diacetate. First synthesized in 2004 and patented in 2006, the compound was developed specifically for topical application. Its molecular weight of 495.58 g/mol falls below the 500 Da threshold associated with penetration through the stratum corneum (the tough outer layer of skin). This was a deliberate design outcome that distinguishes Syn-AKE from larger peptides requiring injection.

Pentapharm Ltd. was subsequently acquired by DSM-Firmenich, and Syn-AKE now sits within that company’s broader cosmetic peptide portfolio. Most published research on the compound originates from manufacturer-sponsored studies. Independent peer-reviewed investigation remains sparse, a critical limitation acknowledged throughout this article.

Research interest in Syn-AKE centers on its application as a non-injectable alternative to botulinum toxin-type agents for investigating expression line formation and neuromuscular modulation in superficial facial muscles. The compound works exclusively through topical application. It has not been studied via injection routes and is structurally and pharmacologically distinct from injectable neuromuscular blocking agents. All current evidence is preclinical or from small-scale human cosmetic studies; no registered human clinical trials have been identified.

One naming note: a small number of sources describe Syn-AKE as a five-amino acid peptide. Primary source documentation, chemical registry records, and manufacturer data consistently classify it as a tripeptide. The tripeptide designation is the scientifically accepted classification.

Syn-AKE Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Syn-AKE consists of three components: beta-alanine, proline, and diaminobutyric acid (Dab) — a non-standard amino acid not commonly found in most proteins. The Dab residue carries a positive electrical charge. This positive charge helps the peptide bind tightly to the acetylcholine receptor’s active site. The compound also has a benzyl amide terminus, meaning the end of the peptide chain is capped with a benzyl-amide group rather than a free acid.

The benzyl amide terminus is important for receptor selectivity. It guides Syn-AKE toward muscular nicotinic acetylcholine receptors (mnAChR) at the neuromuscular junction. This keeps its activity focused on muscle-nerve connections rather than receptors in the brain or other tissue types.

The sub-500 Da molecular weight was a deliberate design objective. Larger peptides face significant barriers to penetrating the stratum corneum (the tough outer layer of skin) and typically require injection to reach their target. By keeping the structure minimal and molecularly compact, researchers created a peptide that can reach superficial dermal layers and nearby nerve-muscle junctions through topical application alone — at least in lab dishes and preliminary human studies.

How Syn-AKE Works: Mechanisms Being Investigated

Syn-AKE operates through several biological pathways. The primary and best-characterized pathway involves blocking a specific receptor at the muscle-nerve junction. Additional pathways identified through computer modeling and lab dish experiments include binding to a longevity-related protein called SIRT1, slowing enzymes that break down collagen, and neutralizing harmful molecules called free radicals. The real-world importance of these secondary pathways during topical use is not yet confirmed.

Nicotinic Acetylcholine Receptor Blocking

The primary mechanism is competitive blocking of the muscular nicotinic acetylcholine receptor (mnAChR) at the neuromuscular junction — the contact point where a nerve tells a muscle to contract.

Here is how the process normally works. A nerve releases acetylcholine, which binds to the receptor. The receptor opens like a gate, letting sodium ions flow into the muscle cell. That ion flow triggers an electrical signal (membrane depolarization — the change in electrical charge across the cell wall that starts the contraction process). The muscle contracts.

Syn-AKE occupies the same binding site that acetylcholine uses, like a key stuck in a lock that stops the right key from entering. Acetylcholine cannot bind. The gate stays closed. Sodium ions do not flow in. The electrical signal does not fire. The muscle contracts less often.

Lab dish studies using cultured muscle cells measured this effect at 0.025% concentration. One dataset recorded a 36% reduction in contraction frequency after one minute, rising to an 82% reduction after two hours. A second dataset from a separate experimental model reported a 71% reduction at one minute and a 58% reduction at two hours. The difference between these results likely reflects different lab setups or cell preparations. Both show partial blocking consistent with a reversible effect — not permanent receptor damage.

At 500 micromolar concentration — that is, 500 millionths of a mole per liter, the amount used in laboratory receptor studies — Syn-AKE blocks approximately 96.5% of receptor activity. The IC50 (the concentration needed to block half the receptor activity) is approximately 180 micromolar. All effects fully reverse when the peptide is removed. No permanent receptor changes are seen in lab dish studies [1].

Downstream Sodium Channel Effects

Because the receptor gate stays closed, voltage-gated sodium channels — separate gates that open in response to the initial electrical signal — also remain shut. Sodium ions cannot flow in through these secondary channels either. The electrical signal cannot travel further along the muscle fiber. This keeps the blocking effect localized to the application site, with no documented impact on muscles elsewhere in the body.

SIRT1 Receptor Binding

A 2023 study used computer modeling and lab dish experiments to examine which proteins Syn-AKE binds to most strongly (PMID 37349941). SIRT1 — a protein involved in cellular aging, stress responses, and longevity signaling — showed the highest binding strength of all proteins tested. The docking score was -9.32 kcal/mol, which means Syn-AKE showed the strongest calculated attachment strength among all proteins examined in that study. Binding was confirmed as stable through computer simulation. The specific attachment points on SIRT1 were residues ASP-111, VAL-175, and HIS-126 — three specific locations on the protein’s surface where Syn-AKE appears to anchor.

Whether topically applied Syn-AKE reaches sufficient concentrations at these targets in living skin to actually activate SIRT1 has not been confirmed. The computer modeling identifies a plausible mechanism, but it cannot confirm what happens during actual use [4, 8].

Matrix Metalloproteinase Modulation

The same 2023 study examined Syn-AKE’s binding to three collagenase enzymes: MMP-1, MMP-8, and MMP-13. Matrix metalloproteinases (MMPs) are enzymes that break down collagen — the structural protein that keeps skin firm. As skin ages, MMP activity increases and collagen degrades faster.

Among the three enzymes tested, Syn-AKE bound most strongly to MMP-13, followed by MMP-8, then MMP-1. MMP-13 binding remained stable through computer simulation. If confirmed in living skin, MMP inhibition would slow collagen breakdown. This would complement the neuromuscular blocking effect by also protecting the structural collagen layer. Whether these concentrations are achievable through topical application has not been established in living animals or people [4, 8].

Antioxidant Activity

The same 2023 study measured Syn-AKE’s ability to neutralize free radicals using the DPPH assay (a standard lab test that measures how well a substance can neutralize a specific unstable molecule used as a stand-in for damaging free radicals). Syn-AKE showed concentration-dependent antioxidant activity. This means the more Syn-AKE was present, the more free radicals it neutralized.

Free radicals damage skin cells over time by attacking lipids, proteins, and DNA. A direct free radical-scavenging effect would add a third independent mechanism to Syn-AKE’s research profile [4, 8].

Collagen Synthesis Stimulation

Manufacturer and primary source documentation indicates increased production of structural proteins in skin fibroblasts (the cells responsible for producing collagen) following Syn-AKE exposure. This would mean active new collagen production, not just protection of existing collagen. Independent validation of this specific effect is limited, and the biological pathway connecting nAChR blocking to fibroblast collagen production has not been clearly described in published literature.

Intracellular Calcium Flux Modulation

When the nAChR gate stays closed, less calcium enters the muscle cell. Calcium acts as a chemical messenger inside cells, triggering contraction and influencing many other cellular processes including cell attachment, growth, and specialization. Reduced calcium entry may influence these downstream processes. This pathway is discussed at an exploratory level; no dedicated studies have quantified its contribution to Syn-AKE’s observed effects.

Syn-AKE Major Areas of Research

Syn-AKE research spans dermatological aging models, neuromuscular pharmacology, topical delivery science, and comparative peptide efficacy. Most research is either manufacturer-sponsored preclinical work or computational studies. The following areas represent the primary directions in which Syn-AKE has been investigated.

Dermatological Aging and Expression Line Research

The central research application for Syn-AKE is studying dynamic expression line formation and reduction in facial skin. Dynamic wrinkles form because muscles beneath the skin contract repeatedly over years. Syn-AKE’s receptor-blocking mechanism targets the muscle-nerve contact point directly.

Research in this area has examined forehead expression lines, periorbital crow’s feet, glabellar frown lines, smile lines, and nasolabial folds. The primary human efficacy study assessed a 4% Syn-AKE cream applied twice daily for 28 days in 50 subjects. The study measured wrinkle depth changes using profilometry — a surface scanning method that produces Ra, Rz, and Rt values representing average roughness, maximum roughness depth, and total roughness height. Wrinkle depth reduction of up to 52% was reported on forehead expression lines. Measurable smoothing was seen in 80% of participants, and wrinkle reduction was evident in 73% of subjects. Effects appeared within one to two hours of application [6].

Emerging research directions include skin texture and tone improvement and potential applications in hyperpigmentation. These represent exploratory areas with very limited supporting data.

Key Research Highlights:

• Up to 52% reduction in forehead wrinkle depth after 28 days at 4% concentration in a manufacturer-sponsored study
• Measurable smoothing effect in 80% of study participants
• Onset of effects within one to two hours of topical application

Neuromuscular Pharmacology Studies

Beyond cosmetic research, Syn-AKE serves as a research tool in neuromuscular pharmacology. Its well-characterized receptor binding profile and reversible blocking make it useful for probing receptor subtype specificity, particularly the epsilon subunit of the muscular nAChR.

Studies have used Syn-AKE as a positive control in comparative nAChR inhibition assays. This means researchers use it as a known benchmark when testing new peptides or molecules. The 2024 in lab dish nAChR assay study (PMC11277145) used Syn-AKE at 500 micromolar as a reference compound, establishing that novel test peptides would need to be more potent than Syn-AKE to achieve equivalent inhibition in shorter time frames.

Exploratory preclinical models have also examined whether Syn-AKE’s mechanism is relevant to neuromuscular disorders including myasthenia gravis, muscular dystrophy, and spasticity research. These remain at the level of early-stage preclinical investigation.

Key Research Highlights:

• Validated as a benchmark reference compound in comparative nAChR inhibition studies
• IC50 of approximately 180 micromolar (the concentration needed to block half of all receptor activity) establishes a quantitative benchmark
• Full reversibility confirmed in multiple lab dish models

Topical Peptide Delivery Research

Syn-AKE sits at the intersection of peptide chemistry and skin delivery science. Its sub-500 Da molecular weight makes it a useful model compound for studying how peptides penetrate through the stratum corneum (the tough outer layer of skin that acts as the primary barrier to absorption).

Research in this area has examined concentration-dependent effects across the 0.025% to 4% range, pH stability within the 3.0-5.5 window, and heat stability profiling up to 70 degrees C. Compatibility with serum, cream, gel, and emulsion bases has been characterized.

General peptide delivery challenges still apply to Syn-AKE despite its size advantage. Compared to classical small-molecule drugs, peptides have relatively large molecular weights. They often have limited ability to pass through oily cell membranes, and they can break down under certain formulation conditions. These factors can limit how deep the peptide penetrates and how much reaches the target tissue. Solutions explored in the broader peptide delivery research literature include chemical modification, encapsulation, and penetration enhancer combinations. None of these approaches have been specifically validated for Syn-AKE in published research.

Key Research Highlights:

• Sub-500 Da molecular weight enables penetration through the outer skin layer without injection
• Effective concentration range of 1-4% in topical cosmetic formulations established
• Compatible with serum, cream, gel, and emulsion delivery systems

Anti-Aging Pathway Studies

The 2023 computer modeling and lab dish study (PMID 37349941) expanded Syn-AKE research beyond its neuromuscular primary mechanism into broader anti-aging signaling pathways. SIRT1 binding and MMP-1, MMP-8, MMP-13 inhibitory binding represent two additional mechanistic dimensions that may contribute to anti-aging effects independently of muscle relaxation.

Antioxidant activity from the DPPH assay adds a protective mechanism against oxidative aging — cell damage caused by free radicals. Together, these findings shift Syn-AKE from a single-mechanism neuromuscular agent toward a multi-target anti-aging research compound in the literature.

The critical limitation throughout this research area is that all mechanistic evidence for SIRT1 binding and MMP inhibition comes from computer modeling and lab dish experiments. Whether these mechanisms operate at the concentrations achievable during topical application in human skin has not been published.

Key Research Highlights:

• SIRT1 binding showed the strongest calculated attachment strength among all proteins tested in the 2023 study
• MMP-13 showed the strongest collagenase inhibitory binding, followed by MMP-8, then MMP-1
• Concentration-dependent antioxidant activity confirmed in lab dish experiments

Comparative Peptide Efficacy Research

Syn-AKE has been compared directly to other topical neuromuscular and anti-wrinkle peptides, most notably acetyl hexapeptide-8 (Argireline), leuphasyl, and pentapeptide-3 (Vialox). Gorouhi and Maibach (2009) reported that a combination of Syn-AKE and leuphasyl produced a 24.62% combined wrinkle reduction effect, compared to 16.26% for Argireline alone. Syn-AKE demonstrated faster onset of visible effects compared to other topical neuromuscular peptides in this comparative analysis and was reported as non-inferior to pentapeptide-3 for smoothing expression lines.

Multi-peptide combination formulations represent an active research direction. Using lower concentrations of several complementary peptides in a single formulation may offer synergistic benefits while staying within practical formulation limits.

Key Research Highlights:

• Syn-AKE outperformed Argireline alone in one comparative study (24.62% combined effect with leuphasyl vs. 16.26% for Argireline)
• Faster onset of visible effects compared to other topical neuromuscular peptides in comparative analysis
• Synergistic effects documented in dual-peptide formulations with leuphasyl

Syn-AKE Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Syn-AKE is designed exclusively for topical application. All published research uses dermal delivery routes. The compound’s molecular weight of 495.58 Da falls just below the 500 Da threshold associated with passive penetration through the stratum corneum (the outer skin barrier), enabling skin absorption without mechanical or chemical penetration aids in most formulation contexts.

Biological activity at target sites is detectable within one to two hours of application in human and lab dish studies, based on muscle contractility data. Quantitative pharmacokinetic parameters — that is, peak blood concentration (Cmax), the time to reach peak concentration (Tmax), and total drug exposure over time (AUC) — have not been established in published peer-reviewed literature for topically applied Syn-AKE.

Distribution and Metabolism

Distribution is characterized as localized to the application site. No significant absorption into the bloodstream has been documented, though detailed tissue distribution data from studies in living animals is absent from the published literature. Penetration depth into dermal layers and actual concentration at the nerve-muscle junction have not been measured in living animals or people.

The metabolic fate of Syn-AKE is incompletely characterized. General breakdown through skin and body enzymes is presumed based on the compound’s structure. Rapid clearance is expected for a small peptide in an enzyme-rich environment.

One notable observation is a duration-potency disconnect. Despite the presumed rapid enzymatic breakdown of the peptide, effects on muscle contractility persist for hours after single application, and cumulative effects develop over weeks of repeated use. Possible explanations include retention within dermal tissue compartments, formation of active breakdown products, or downstream signaling that continues after the parent compound has cleared. None of these explanations has been confirmed through labeled peptide studies or direct breakdown product analysis.

Delivery Methods Under Investigation

• Topical cream: Most common vehicle in human studies; 4% concentration used in primary efficacy study
• Topical serum: Used in facial anti-aging research; allows higher concentrations and faster contact with skin
• Gel formulations: Examined for localized application to specific wrinkle sites
• Emulsion bases: Used in cosmetic formulation optimization research
• Raw powder reconstitution: Used in formulation development and concentration-ranging research

Syn-AKE is not studied via injection routes and is not an injectable compound. This distinction is fundamental to its pharmacological profile and regulatory classification.

Excretion and Clearance

Breakdown products from Syn-AKE metabolism are presumed to follow normal amino acid and small peptide elimination pathways, with kidney clearance probable for any fragments that enter the bloodstream. No accumulation has been detected in repeated-use manufacturer studies. Labeled peptide distribution studies, which would provide precise excretion data, have not been published. Detailed elimination data from independent peer-reviewed studies is absent.

Syn-AKE Research Limitations and Evidence Gaps

Evidence Quality Issues

The most significant limitation in Syn-AKE research is the manufacturer-dominated evidence base. Most efficacy and safety data comes from Pentapharm and DSM-Firmenich sponsored studies rather than independent peer-reviewed trials. The primary human efficacy finding (up to 52% wrinkle depth reduction) comes from a single 50-subject study with no independent replication published in the literature.

No registered Phase I, II, or III clinical trials for Syn-AKE appear on ClinicalTrials.gov. Research may exist as unregistered, unpublished, or using alternative terminology, but the absence of registered trials means the compound lacks the transparency and oversight standards associated with pharmaceutical drug development.

The strongest mechanistic data beyond neuromuscular activity — specifically SIRT1 binding and MMP inhibition — is entirely from computer modeling and lab dish experiments. Confirmation in living animals or people is absent.

Mechanistic Gaps

The precise binding site on the mnAChR epsilon subunit has not been confirmed through X-ray crystallography. The relative contributions of SIRT1 binding, MMP inhibition, and neuromuscular effects to any observed outcome remain unquantified. Whether MMP inhibition occurs at concentrations achievable during topical application is uncertain. Skin penetration depth and target tissue concentrations at the neuromuscular junction have not been quantified in any published study in living animals or people.

Two lab dish datasets report different percentage reductions in muscle contraction at identical concentrations, likely reflecting experimental model differences. This discrepancy has not been formally resolved in published literature.

Pharmacokinetic Gaps

Quantitative pharmacokinetic parameters — peak concentration (Cmax), time to peak (Tmax), and total exposure (AUC) — for topical Syn-AKE application have not been established. Half-life in human skin has not been characterized. The duration-potency disconnect (effects persisting well beyond the expected breakdown time of the peptide) has no published mechanistic explanation. Labeled peptide distribution studies required for precise excretion data have not been published.

Safety Data Gaps

No independent clinical trials examining safety, tolerability, or adverse effects of Syn-AKE have been published. Chronic use effects beyond six months are not systematically studied. Potential for localized muscle atrophy with extended application is unknown. Drug interaction potential with topical or systemic medications is uncharacterized. Pregnancy and lactation safety is completely unstudied. Sensitization and allergic reaction incidence in large populations is not well documented. The Cosmetic Ingredient Review (CIR) Expert Panel has not formally evaluated Syn-AKE.

Formulation Challenges

Despite the molecular weight advantage, peptide delivery challenges remain. Higher molecular weight compared to classical small molecule drugs, limited ability to cross oily cell membranes, and formulation sensitivity may limit actual penetration depth and bioavailability at target tissue. Penetration enhancer compatibility and encapsulation strategies have not been specifically validated for Syn-AKE in published research.

Areas Needing Further Investigation

• Independent replication of the primary human efficacy study under registered trial conditions
• Measurement of actual penetration depth and nerve-muscle junction concentration in living skin
• Formal pharmacokinetic characterization (Cmax, Tmax, AUC, half-life) for topical application
• Systematic long-term safety studies beyond six months
• Mechanistic explanation for the duration-potency disconnect
• Confirmation of SIRT1 activation and MMP inhibition at achievable topical concentrations in living skin
• Independent CIR safety assessment

Syn-AKE Regulatory and Research Status

Current Classification

FDA Status

Syn-AKE is classified as a cosmetic ingredient when used in topical formulations in the United States. As a cosmetic ingredient, it does not require pre-market approval. Therapeutic or drug claims (such as treating wrinkles as a medical condition) cannot be made under cosmetic classification. Generally Recognized as Safe (GRAS) status has not been established for Syn-AKE specifically. The compound is subject to cosmetic ingredient safety standards, which are less stringent than pharmaceutical drug efficacy and safety requirements. Outside of cosmetic formulation contexts, Syn-AKE is available for research use only.

WADA Status

Syn-AKE is not listed on the World Anti-Doping Agency (WADA) Prohibited List. It is a topically applied cosmetic research peptide with no documented performance-enhancing application in competitive athletics. Athletes subject to anti-doping testing should nonetheless verify current WADA documentation independently, as prohibited substance lists are updated annually.

International Perspective

Within EU jurisdiction, Syn-AKE is regulated as a cosmetic ingredient under the EU Cosmetics Regulation framework, which requires safety substantiation before market placement. Regulatory acceptance across major international markets reflects the cosmetic classification rather than pharmaceutical approval. No major regulatory body has classified Syn-AKE as a pharmaceutical drug.

Research Community Approach

Academic and independent research using Syn-AKE is limited relative to more extensively studied peptides with registered clinical trial programs. Most published research originates from the manufacturer. Independent investigations using Syn-AKE as a reference or probe compound in nAChR pharmacology studies represent the clearest area of non-manufacturer research activity. Institutional use for legitimate peptide delivery and neuromuscular pharmacology research requires compliance with applicable institutional biosafety and ethical oversight protocols.

Future Research Directions

The most important gap requiring future research is a properly registered, independently conducted human clinical trial assessing both efficacy and safety of topical Syn-AKE across diverse populations and longer time frames. Studies in living subjects using labeled peptide would resolve the penetration depth and duration-potency questions. Formal CIR review would provide an independent safety benchmark. As interest in non-injectable neuromuscular modulation expands within dermatological research, Syn-AKE’s established lab dish profile positions it as a candidate for more rigorous clinical investigation.

Syn-AKE Key Research Findings

Primary Human Efficacy Study (28-Day, 4% Cream)

Research Focus: Reduction in forehead expression line depth following twice-daily application of 4% Syn-AKE cream

Key Results: Wrinkle depth reduction of up to 52% measured by profilometry after 28 days; smoothing effect measurable in 80% of participants; wrinkle reduction evident in 73% of subjects; onset of visible effects within one to two hours of application; performance superior to acetyl hexapeptide-8 (Argireline) in head-to-head within-study comparison

Significance: Provides the primary human evidence base for Syn-AKE’s wrinkle-reducing activity and establishes the 4% twice-daily protocol as the reference research design

Limitations: Single manufacturer-sponsored study; 50-subject sample; no independent replication published; no placebo-controlled registered trial design; long-term effects not assessed [6]

Lab Dish Muscle Cell Contractility Study (Pentapharm Technical Bulletin, 2006)

Research Focus: Quantification of Syn-AKE effects on contraction frequency in cultured innervated muscle cells

Key Results: Up to 71-82% reduction in contractile activity within one to two hours at 0.025% concentration; two datasets reporting slightly different profiles (36%/82% vs. 71%/58% across time points) likely reflecting model differences; full reversibility confirmed upon peptide withdrawal; no cell death at tested concentrations

Significance: Establishes rapid-onset, sustained-duration receptor blocking profile and confirms reversibility as a key safety-relevant characteristic distinguishing Syn-AKE from permanent neuromuscular blocking agents

Limitations: Lab dish cultured cell model; discrepancy between two datasets not formally resolved; relevance to the nerve-muscle junction in living human skin not directly established [1]

2023 Computer Modeling and Lab Dish Multi-Target Analysis (PMID 37349941)

Research Focus: Computational docking and simulation analysis of Syn-AKE binding to SIRT1, MMP-1, MMP-8, and MMP-13; lab dish antioxidant, cytotoxicity, and genotoxicity testing

Key Results: SIRT1 showed the highest calculated binding strength among all proteins tested; stable binding confirmed at three specific residues over a 50-nanosecond simulation; MMP-13 showed stronger binding than MMP-8, which showed stronger binding than MMP-1, with stable MMP-13 binding confirmed; concentration-dependent antioxidant activity confirmed; no cell toxicity at cosmetic-use concentrations; no mutagenic activity in Ames genotoxicity test

Significance: First published multi-target mechanistic characterization of Syn-AKE; expands research profile beyond neuromuscular activity to anti-aging signaling and collagen protection pathways

Limitations: Computer modeling and lab dish methods only; confirmation in living animals or people is absent; relevance of SIRT1 and MMP binding at achievable topical concentrations unconfirmed [4, 8]

Comparative Peptide Efficacy Analysis (Gorouhi and Maibach, 2009)

Research Focus: Comparative wrinkle reduction efficacy of Syn-AKE against Argireline, leuphasyl, and pentapeptide-3 (Vialox) in topical anti-aging formulations

Key Results: Syn-AKE combined with leuphasyl produced 24.62% combined wrinkle reduction versus 16.26% for Argireline alone; Syn-AKE showed faster visible effect onset than other topical neuromuscular peptides; non-inferior to pentapeptide-3 for expression line smoothing; synergistic effects documented in dual-peptide formulation

Significance: Positions Syn-AKE within the topical neuromuscular peptide landscape and identifies combination formulation as a productive research direction

Limitations: Review and comparative analysis rather than head-to-head registered clinical trial; individual study methodologies vary across compared compounds [3]

2024 Lab Dish nAChR Reference Assay (PMC11277145)

Research Focus: Characterization of Syn-AKE as a reference compound for muscular nAChR inhibition in a comparative peptide potency study

Key Results: At 500 micromolar, Syn-AKE blocks 96.5% of receptor activity, reducing it to approximately 3.5% of baseline; IC50 (the concentration needed to block half of all receptor activity) approximately 180 micromolar; used as a benchmark against which novel test peptides were compared

Significance: Provides quantitative receptor pharmacology data for Syn-AKE and establishes its utility as a reference compound in nAChR research, confirming the primary mechanism in a format independent of the original manufacturer

Limitations: Lab dish assay; high concentration used (500 micromolar) reflects pharmacology research conditions rather than concentrations in topical formulations [9]

PMC7662462 Review (2020)

Research Focus: Review of lab dish and manufacturer data for Syn-AKE and other topical neuromuscular peptides

Key Results: Cites 52% wrinkle reduction after 28 days at 0.5 mM; notes absence of independent clinical papers at time of publication; characterizes Syn-AKE mechanism as reducing muscle tone and wrinkle formation through a mechanism similar to Botox

Significance: Provides independent academic acknowledgment of Syn-AKE’s reported efficacy while explicitly noting the absence of independent clinical validation

Limitations: Review of manufacturer data rather than independent trial; calls for additional efficacy and safety studies [10]

Frequently Asked Questions

What is Syn-AKE?

Syn-AKE is a synthetic tripeptide designed to mimic the neuromuscular blocking activity of a compound found in Temple Viper venom. It works by temporarily reducing how often muscle cells contract, by blocking the receptor that normally receives the nerve signal to contract. Researchers study it primarily as a topical compound for investigating expression line formation and reduction in skin aging models.

How does Syn-AKE differ from Botox?

Botox (botulinum toxin) is an injectable neurotoxin that permanently disables a specific protein required for nerve signal transmission, producing long-lasting muscle paralysis at the injection site. Syn-AKE is a topical peptide that blocks acetylcholine receptors reversibly, with effects that reverse when the compound is removed. Syn-AKE has not been studied via injection and is not classified as a drug. The two compounds target different molecular sites through fundamentally different mechanisms, and Syn-AKE produces partial, reversible receptor blocking rather than the complete, prolonged neuromuscular blockade associated with botulinum toxin.

What does the research say about Syn-AKE’s safety?

Available safety data includes lab dish cytotoxicity and genotoxicity testing showing no adverse effects at cosmetic-use concentrations. The compound shows full reversibility in muscle cell studies with no permanent receptor modification. Anecdotal reports mention skin reactions including redness, itching, and stinging in some sensitive individuals. No independent clinical trials specifically evaluating Syn-AKE safety, tolerability, or adverse effect rates have been published. Chronic use effects beyond six months, pregnancy safety, and drug interaction potential remain completely unstudied.

Is Syn-AKE approved for human use?

In cosmetic formulation contexts, Syn-AKE is regulated as a cosmetic ingredient in the United States and EU, which does not require pre-market approval. It is not approved as a pharmaceutical drug by the FDA or any equivalent agency. No registered Phase I, II, or III clinical trials for Syn-AKE appear in public databases. Outside of cosmetic use contexts, Syn-AKE is available for laboratory research purposes only.

How long has Syn-AKE been studied?

Syn-AKE was first synthesized in 2004 and patented in 2006 by Pentapharm Ltd. in Switzerland. The primary human efficacy study data originates from approximately 2009. A key multi-target computer modeling and lab dish study was published in 2023, expanding understanding of the compound’s potential biological targets beyond its primary neuromuscular mechanism. Most of the published research base spans from 2006 to 2024, with the majority of work occurring within the manufacturer’s research program rather than independent academic institutions.

Explore the complete Peptide Research Library for additional peer-reviewed studies and compound analyses.

References

1. Scandasia. Syn-AKE peptide molecular properties and expanding research implications. Source

2. Revival Labs. Unlocking the secrets of Syn-AKE: the revolutionary peptide for skin care. Source

3. Gorouhi, F., & Maibach, H.I. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 31(5), 327-345. PubMed

4. Gok, M., et al. (2023). Anti-aging activity of Syn-Ake peptide by in silico and in vitro analysis. Semantic Scholar. Source

5. DSM-Firmenich. Syn-AKE product information. Source

6. DSM-Firmenich. Syn-AKE clinical study data (4% cream, 28-day, 50 subjects). Referenced via DSM-Firmenich product documentation. Source

7. PMC11762834 (2024). Syn-AKE reduces facial muscle movement for expression wrinkle prevention; calls for additional efficiency and safety studies. PubMed Central

8. Gok, M., et al. (2023). Anti-aging activity of Syn-Ake peptide by in silico and in vitro analysis. Journal of Biomolecular Structure and Dynamics, 42(10), 5233-5246. PubMed

9. PMC11277145 (2024). In vitro nAChR inhibition study; Syn-AKE used as positive control; reduces nicotinic response to approximately 3.5% at 500 micromolar. PubMed Central

10. PMC7662462 (2020). Review of in vitro and in vivo manufacturer data; cites 52% wrinkle reduction after 28 days; notes no independent clinical papers. PubMed Central

11. La Prensa. Syn-AKE peptide: a bio-inspired compound with potential in neuromuscular and skin cell research. Source